Commentary

Video

Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer

Author(s):

Christian Marth, MD, PhD

Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.

Related Videos
Matthew Powell, MD
Laura J. Chambers, DO
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Maurie Markman, MD
Salman R. Punekar, MD
Bhavana Pothuri, MD
David M. O’Malley, MD
Suresh Ramalingam, MD, and Chandler Park, MD
Amin Nassar, MD
Related Content
FDA accepts rivoceranib/camrelizumab NDA for HCC, acalabrutinib triplet yields 100% ORR in untreated mantle cell lymphoma, and more from OncLive this week.
October 26th 2024

The OncFive: Top Oncology Articles for the Week of 10/20

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Maurie Markman, MD
October 24th 2024

The Escalating Need for Robust Decision Support in Oncology: Ovarian Cancer as an Example

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Maurie Markman, MD
October 21st 2024

Markman’s Take: Vibostolimab in dMMR Endometrial Cancer, Adjuvant Chemo in Cervical Cancer, and More

Matt Sause, chief executive officer, Roche Diagnostics
September 23rd 2024

CINtec PLUS Receives WHO Endorsement in Cervical Cancer Prevention Guidelines